Medical Treatments for Prostate Cancer

There are many different medical treatments for prostate cancer that involve the clinical care of a healthcare professional. These treatments include expectant therapy, surgery, radiation therapy, hormone therapy, and chemotherapy. Expectant therapy is to carefully observe and monitor the prostate cancer. Because prostate cancer cells often spread very slowly, many older men who have the disease may not need more extensive treatment. However, expectant therapy usually includes routine physician examinations, including digital rectal exams and PSA tests. The different types of surgery for prostate cancer are radical prostatectomy - an open-surgery procedure in which the entire prostate gland and surrounding tissue are removed. Transurethral resection of the prostate (TURP) - surgery to remove part of the prostate gland that surrounds the urethra. Cryosurgery - this procedure involves killing the cancer cells by freezing them with a small metal tool placed in the tumor. Side effects of prostate cancer surgery include incontinence and impotence. Incontinence is the inability to control urine and may result in dribbling of urine, especially immediately after surgery. Normal control usually returns within weeks or months after surgery. Impotence is the inability to achieve an erection. For a month, or so, after surgery, most men are not able to get an erection. Eventually, approximately 40 to 60 percent of men will be able to get an erection sufficient for sexual intercourse, but without ejaculation of semen, since removal of the prostate gland prevents that process.

Radiation therapy uses high energy rays to kill or shrink cancer cells, and to decrease their ability to divide. Radiation is often used to treat prostate cancer that is still confined to the prostate gland, or has spread only to nearby tissue. If the disease is advanced, radiation may be used to reduce the size of the tumor and to provide relief from symptoms. Possible side effects of radiation for prostate cancer may include diarrhea, with or without blood in the stool, and colitis, problems associated with urination, a degree of impotence (inability to get an erection), which may occur within two years of radiation therapy.

The goal of hormone therapy is to lower the level of male hormones in the body, particularly testosterone. Hormone therapy does not cure the cancer, and is often used to treat persons whose cancer has spread or recurred after treatment. Produced mainly in the testicles, testosterone causes prostate cancer cells to grow. Thus, reduced testosterone levels can make the prostate cancer shrink and become less active. Most studies show that hormone therapy works better if it is started early. Chemotherapy is the use of powerful, anti-cancer medications to kill cancer cells.. Hospitalization may be needed to monitor treatment and chemotherapy's side effects. Common side effects of chemotherapy include: nausea and vomiting, hair loss, anemia, reduced ability of blood to clot, mouth sores, increased likelihood of developing infections, fatigue. Most side effects disappear once treatment is stopped.

bother score prostate
Measuring disease specific quality of life in localized prostate
prostate cancer patients. Methods: Scales on urinary and bowel function and bother from the UCLA .. tion and bother scores, but not bowel function and

UroToday - Effect of Tamsulosin Hydrochloride on Lower Urinary
However, the international prostate symptom score (IPSS) used for evaluating LUTS does not always reflect the level of patient bother, and improvement in

The Journal of Urology : CLINICAL UROLOGY: This Month in Clinical
URINARY FUNCTION AND BOTHER SCORES LOWER FOR PROSTATECTOMY. Urinary function and bother in 564 men with prostate cancer treated with radiotherapy or radical

Prostate Cancer and Prostatic Diseases - Sexual function following
Each Prostate Cancer Index domain is scored from 0 to 100 points, With regard to sexual bother scores, Japanese and American men did not differ at

Prostate Cancer and Prostatic Diseases - Quality of life in young
Urinary and sexual function and bother were measured with the UCLA Prostate Cancer Index (PCI).14 The PCI scores range from 0 to 100, with higher values

Validity of the ÁœBother ScoreÁ« in the Evaluation and Treatment of
Correlation of IPSS bother question scores with IPSS severity in the MSAM-7 study. IPSS, International Prostate Symptom Score; MSAM-7, Multinational Survey

Prostate Size: Does It Matter?
One such example is the issue of prostate size and its role in the diagnostic . the placebo-treated patients experienced a decrease in the bother score

á© A. HENDERSON*Á , R.W. LAINGÁ , S.E.M. LANGLEY S. BRODY
the bother score will reflect the effect of. incontinence. This has not been established. and when studies using the validated UCLA. prostate cancer index

Larger urethral catheter size leads to fossa navicularis stricture
Association symptom score, urinary bother score, preopera-. tive prostate-speciWc antigen, operative time, estimated. blood loss, cautery use, prostate size

CAT.INIST
The impact of baseline (age, prior AUR, prostate-specific antigen tertiles, lower urinary tract symptoms severity, and bother score) and dynamic

Takegami,M
A sexual function score of 18 on UCLA PCI corresponded to an Extended Prostate Cancer Index Composite score of 12 and a sexual bother score of 50 on UCLA

OncoLink | The Web's First Cancer Resource
Is Previous Transurethral Resection of the Prostate a Contraindication to when the data is presented as a mean UCLA urinary function/bother score.

KoreaMed - Basic Search
such as the symptom score, storage symptom score, voiding symptom score, bother score, peak flow, post-voiding residuals and prostate volume,

Bladder Outlet Obstruction
BPH is still considered an appropriate description of the prostate when referring to The bother score is the symptom score with the word ÁœbotherÁ« added.

Is There a Relationship between the Amount of Tissue Removed at
Patients were assessed preoperatively with the International Prostate Symptom Score (IPSS), the American Urological Association Bother Score (AUA-BS) and

ScienceDirect - International Journal of Radiation Oncology
UCLA Prostate Cancer Index, urinary bother Full Size Table. Univariate analysis demonstrated there to be less impact on urinary function and bother scores

IngentaConnect Quality of life in T1-3N0 prostate cancer patients
Results: The mean sexual function score was 15.4, with a bother score of 42. cohorts of prostate cancer patients undergoing radiotherapy or observation.

IngentaConnect Correlation of transrectal ultrasound measurements
Correlation of transrectal ultrasound measurements of prostate and transition zone size with symptom score, bother score, urinary flow rate, and post-void


bother score prostate
green laser prostatectomy
cancer prostate testosterone treatment
electrical stimulation of prostate
benign hypertrophy prostate treatment